{"id":48586,"date":"2025-11-18T20:33:40","date_gmt":"2025-11-18T12:33:40","guid":{"rendered":"https:\/\/flcube.com\/?p=48586"},"modified":"2025-11-18T20:33:41","modified_gmt":"2025-11-18T12:33:41","slug":"hengruis-hrs-6209-cdk4-inhibitor-wins-nmpa-nod-for-breast-cancer-combo-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48586","title":{"rendered":"Hengrui&#8217;s HRS-6209 CDK4 Inhibitor Wins NMPA Nod for Breast Cancer Combo Trial"},"content":{"rendered":"\n<p><strong>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG: 1276<\/a>) announced that <strong>HRS\u20116209 capsules<\/strong>, a novel selective <strong>CDK4 inhibitor<\/strong>, received <strong>NMPA clinical trial approval<\/strong> for use in combination with <strong>HRS\u20112189 tablets<\/strong> and an aromatase inhibitor for the treatment of breast cancer, marking a potential first\u2011in\u2011class advancement in CDK4\u2011selective therapy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>HRS\u20116209 capsules + HRS\u20112189 tablets<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Jiangsu Hengrui Pharmaceuticals<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial approval (Phase\u202f1b\/2)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Breast cancer (in combination with aromatase inhibitor)<\/td><\/tr><tr><td><strong>Innovation<\/strong><\/td><td><strong>First\u2011in\u2011class<\/strong> selective CDK4 inhibitor and first\u2011in\u2011class KAT6 inhibitor globally<\/td><\/tr><tr><td><strong>Next Step<\/strong><\/td><td>Initiate patient enrollment Q1\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile\">Drug Profile<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-hrs-6209-cdk4-inhibitor\">HRS\u20116209 (CDK4 Inhibitor)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Potently inhibits <strong>CDK4\/cyclinD<\/strong> complex and downstream signaling, inducing G1\u2011phase cell cycle arrest and anti\u2011tumor activity<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> <strong>Improved selectivity<\/strong> for CDK4 vs. CDK6\/cyclinD3 pathway compared to existing CDK4\/6 inhibitors, potentially reducing hematologic toxicity (neutropenia, thrombocytopenia)<\/li>\n\n\n\n<li><strong>Global Status:<\/strong> <strong>No similar CDK4\u2011selective product<\/strong> approved worldwide<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-hrs-2189-kat6-inhibitor\">HRS\u20112189 (KAT6 Inhibitor)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Inhibits histone lysine acetylation, regulating expression of various downstream oncogenes to exert anti\u2011tumor effects<\/li>\n\n\n\n<li><strong>Global Status:<\/strong> <strong>No drugs targeting the same pathway<\/strong> have been approved for marketing worldwide<\/li>\n\n\n\n<li><strong>Intended Use:<\/strong> Treatment of advanced malignancies, providing a novel epigenetic approach<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-plan\">Clinical Development Plan<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Phase<\/strong><\/td><td>Phase\u202f1b\/2 (dose\u2011finding and expansion)<\/td><\/tr><tr><td><strong>Population<\/strong><\/td><td>HR\u2011positive, HER2\u2011negative advanced breast cancer patients<\/td><\/tr><tr><td><strong>Combination Regimen<\/strong><\/td><td>HRS\u20116209 + HRS\u20112189 + aromatase inhibitor (letrozole or anastrozole)<\/td><\/tr><tr><td><strong>Endpoints<\/strong><\/td><td>Safety, tolerability, ORR, PFS, biomarker analysis (CDK4\/6 resistance mutations)<\/td><\/tr><tr><td><strong>Rationale<\/strong><\/td><td>Dual cell\u2011cycle and epigenetic blockade may overcome resistance to standard CDK4\/6 inhibitors<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Addressable Market:<\/strong> China breast cancer incidence exceeded <strong>420,000 new cases<\/strong> in 2024; HR+\/HER2\u2011 subtype accounts for ~70% of cases, with many developing CDK4\/6 inhibitor resistance.<\/li>\n\n\n\n<li><strong>CDK4\/6 Market:<\/strong> Global CDK4\/6 inhibitor sales topped <strong>$9\u202fbillion<\/strong> in 2024 (Pfizer\u2019s Ibrance, Novartis\u2019s Kisqali, Eli Lilly\u2019s Verzenio), but all carry significant hematologic toxicity.<\/li>\n\n\n\n<li><strong>Revenue Forecast:<\/strong> Analysts project <strong>\u00a52.0\u20112.5\u202fbillion<\/strong> (~US$275\u2011340\u202fmillion) China peak sales potential for HRS\u20116209 by 2033 if it demonstrates superior safety and efficacy in resistant patients.<\/li>\n\n\n\n<li><strong>Competitive Edge:<\/strong> First <strong>CDK4\u2011selective<\/strong> agent could capture the <strong>30\u201140%<\/strong> of patients who discontinue CDK4\/6 inhibitors due to toxicity, while HRS\u20112189 adds a unique epigenetic component.<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Dual first\u2011in\u2011class assets strengthen Hengrui\u2019s oncology portfolio ahead of its <strong>H\u2011share listing<\/strong> and global partnership discussions.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding HRS\u20116209 and HRS\u20112189\u2019s clinical development, regulatory pathway, and commercial potential. Actual results may differ materially due to risks including clinical trial outcomes, safety profiles, and competitive dynamics in the CDK inhibitor market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2025111700966_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025111700966_c.\"><\/object><a id=\"wp-block-file--media-f550a5ed-f558-47de-a639-d0c772b370cd\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2025111700966_c.pdf\">2025111700966_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2025111700966_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-f550a5ed-f558-47de-a639-d0c772b370cd\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS\u20116209 capsules, a novel&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48592,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,29,2586,4228,852],"class_list":["post-48586","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-combination-therapy","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hengrui&#039;s HRS-6209 CDK4 Inhibitor Wins NMPA Nod for Breast Cancer Combo Trial - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS\u20116209 capsules, a novel selective CDK4 inhibitor, received NMPA clinical trial approval for use in combination with HRS\u20112189 tablets and an aromatase inhibitor for the treatment of breast cancer, marking a potential first\u2011in\u2011class advancement in CDK4\u2011selective therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48586\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui&#039;s HRS-6209 CDK4 Inhibitor Wins NMPA Nod for Breast Cancer Combo Trial\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS\u20116209 capsules, a novel selective CDK4 inhibitor, received NMPA clinical trial approval for use in combination with HRS\u20112189 tablets and an aromatase inhibitor for the treatment of breast cancer, marking a potential first\u2011in\u2011class advancement in CDK4\u2011selective therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48586\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-18T12:33:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-18T12:33:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1801-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48586#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48586\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui&#8217;s HRS-6209 CDK4 Inhibitor Wins NMPA Nod for Breast Cancer Combo Trial\",\"datePublished\":\"2025-11-18T12:33:40+00:00\",\"dateModified\":\"2025-11-18T12:33:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48586\"},\"wordCount\":437,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48586#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1801-1.webp\",\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"Combination therapy\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48586#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48586\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48586\",\"name\":\"Hengrui's HRS-6209 CDK4 Inhibitor Wins NMPA Nod for Breast Cancer Combo Trial - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48586#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48586#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1801-1.webp\",\"datePublished\":\"2025-11-18T12:33:40+00:00\",\"dateModified\":\"2025-11-18T12:33:41+00:00\",\"description\":\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS\u20116209 capsules, a novel selective CDK4 inhibitor, received NMPA clinical trial approval for use in combination with HRS\u20112189 tablets and an aromatase inhibitor for the treatment of breast cancer, marking a potential first\u2011in\u2011class advancement in CDK4\u2011selective therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48586#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48586\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48586#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1801-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1801-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Hengrui's HRS-6209 CDK4 Inhibitor Wins NMPA Nod for Breast Cancer Combo Trial\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48586#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui&#8217;s HRS-6209 CDK4 Inhibitor Wins NMPA Nod for Breast Cancer Combo Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui's HRS-6209 CDK4 Inhibitor Wins NMPA Nod for Breast Cancer Combo Trial - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS\u20116209 capsules, a novel selective CDK4 inhibitor, received NMPA clinical trial approval for use in combination with HRS\u20112189 tablets and an aromatase inhibitor for the treatment of breast cancer, marking a potential first\u2011in\u2011class advancement in CDK4\u2011selective therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48586","og_locale":"en_US","og_type":"article","og_title":"Hengrui's HRS-6209 CDK4 Inhibitor Wins NMPA Nod for Breast Cancer Combo Trial","og_description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS\u20116209 capsules, a novel selective CDK4 inhibitor, received NMPA clinical trial approval for use in combination with HRS\u20112189 tablets and an aromatase inhibitor for the treatment of breast cancer, marking a potential first\u2011in\u2011class advancement in CDK4\u2011selective therapy.","og_url":"https:\/\/flcube.com\/?p=48586","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-18T12:33:40+00:00","article_modified_time":"2025-11-18T12:33:41+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1801-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48586#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48586"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui&#8217;s HRS-6209 CDK4 Inhibitor Wins NMPA Nod for Breast Cancer Combo Trial","datePublished":"2025-11-18T12:33:40+00:00","dateModified":"2025-11-18T12:33:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48586"},"wordCount":437,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48586#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1801-1.webp","keywords":["Cancer","Clinical trial approval \/ initiation","Combination therapy","Hengrui Pharmaceuticals","HKG: 1276","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48586#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48586","url":"https:\/\/flcube.com\/?p=48586","name":"Hengrui's HRS-6209 CDK4 Inhibitor Wins NMPA Nod for Breast Cancer Combo Trial - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48586#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48586#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1801-1.webp","datePublished":"2025-11-18T12:33:40+00:00","dateModified":"2025-11-18T12:33:41+00:00","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS\u20116209 capsules, a novel selective CDK4 inhibitor, received NMPA clinical trial approval for use in combination with HRS\u20112189 tablets and an aromatase inhibitor for the treatment of breast cancer, marking a potential first\u2011in\u2011class advancement in CDK4\u2011selective therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48586#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48586"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48586#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1801-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1801-1.webp","width":1080,"height":608,"caption":"Hengrui's HRS-6209 CDK4 Inhibitor Wins NMPA Nod for Breast Cancer Combo Trial"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48586#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui&#8217;s HRS-6209 CDK4 Inhibitor Wins NMPA Nod for Breast Cancer Combo Trial"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1801-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48586","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48586"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48586\/revisions"}],"predecessor-version":[{"id":48593,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48586\/revisions\/48593"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48592"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48586"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48586"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48586"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}